Obe-cel CAR T-cell therapy in B-cell ALL

KEY TAKEAWAYS

- **76%** of patients had **no or very few signs of leukemia** in their blood or bone marrow after obe-cel treatment
- Having **a very low number of leukemia cells** left after treatment (MRD negative) was linked to being **leukemia-free for longer** and **living longer**

Study overview

This analysis looked at **obecabtagene autoleucel** (obe-cel) as a treatment for **adults with relapsed** (leukemia came back) or **refractory** (treatment-resistant) **B-cell ALL.**

What is obe-cel?

- Obe-cel is a type of **CAR T-cell therapy**
- CAR T-cell therapy uses **a patient's own immune cells,** which are modified to better **recognize** and **attack cancer cells**



Who participated in this study?

127 people

with **relapsed or refractory** (R/R) **B-ALL**

How effective was obe-cel?

of patients had a **complete remission** or nearly complete remission.

Which means they had no visible signs of leukemia in their blood or bone marrow after obe-cel treatment.

What is MRD?

- **MRD** stands for **M**easurable **R**esidual **D**isease
- It is the **amount of cancer cells remaining after treatment** and is measured by very sensitive tests

Why is MRD important?

This analysis found that in:

of patients who improved the most with treatment, their **cancer cells were undetectable** using sensitive tests (known as **MRD negative**)

Patients with the **deepest MRD response** (fewest cancer cells left):

- Were **leukemia-free for longer:**

18 months (Deep MRD response) VS **5 months** (Less deep MRD response)

- **Lived longer – amount of people alive** after an average of **22 months:**



Deep MRD response — Less deep MRD response

WHAT DOES THIS MEAN FOR PATIENTS?

- Obe-cel CAR T-cell therapy resulted in **over 3/4** of adults with R/R B-cell ALL improving so much that they went into remission
- Achieving a **deep MRD response** (no detectable cancer cells) was linked to being **leukemia-free for longer** and **living longer**
- This suggests that achieving a **deep level of MRD** may be an important **treatment goal** for **improving outcomes** in the future

Reference: *Jabbour E, et al. Presentation at the 66th ASH Annual Meeting and Exposition, San Diego, December 9, 2024. Abstract #963.*

ALAN
Acute Leukemia Advocates Network